Biotech Values

[DewDiligence]

> DNA – I think in the next two weeks, the following positive catalysts could push the price up around 10% (JMHO)
Lucentis approval with a clean and wide label (1+ billion opp)
Avastin approval in 2nd line mCRC (250 million opp)
Herceptin approval in adjuvant BC (1+ billion opp)<

The PDUFA dates are June 20 for Avastin, June 30 for Lucentis, and sometime in September for Herceptin. It sounds like you think the Herceptin approval could come well before the PDUFA date.